430 related articles for article (PubMed ID: 9438229)
21. From symptoms to social functioning: differential effects of antidepressant therapy.
Kasper S
Int Clin Psychopharmacol; 1999 May; 14 Suppl 1():S27-31. PubMed ID: 10468326
[TBL] [Abstract][Full Text] [Related]
22. Chairman's overview. The place of reboxetine in antidepressant therapy.
Montgomery SA
J Clin Psychiatry; 1998; 59 Suppl 14():26-9. PubMed ID: 9818628
[TBL] [Abstract][Full Text] [Related]
23. The need for new and better antidepressants: reboxetine a new option.
Dencker SJ
Acta Psychiatr Scand Suppl; 2000; 402():6-11. PubMed ID: 10901153
[TBL] [Abstract][Full Text] [Related]
24. Reboxetine: a review of antidepressant tolerability.
Mucci M
J Psychopharmacol; 1997; 11(4 Suppl):S33-7. PubMed ID: 9438231
[TBL] [Abstract][Full Text] [Related]
25. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.
Eyding D; Lelgemann M; Grouven U; Härter M; Kromp M; Kaiser T; Kerekes MF; Gerken M; Wieseler B
BMJ; 2010 Oct; 341():c4737. PubMed ID: 20940209
[TBL] [Abstract][Full Text] [Related]
26. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.
Rampello L; Chiechio S; Nicoletti G; Alvano A; Vecchio I; Raffaele R; Malaguarnera M
Psychopharmacology (Berl); 2004 Apr; 173(1-2):73-8. PubMed ID: 14685645
[TBL] [Abstract][Full Text] [Related]
27. Is there a role for a pure noradrenergic drug in the treatment of depression?
Montgomery SA
Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S3-9; discussion S71-3. PubMed ID: 9169305
[TBL] [Abstract][Full Text] [Related]
28. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.
Versiani M; Mehilane L; Gaszner P; Arnaud-Castiglioni R
J Clin Psychiatry; 1999 Jun; 60(6):400-6. PubMed ID: 10401920
[TBL] [Abstract][Full Text] [Related]
29. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder.
Juckel G; Pogarell O; Augustin H; Mulert C; Müller-Siecheneder F; Frodl T; Mavrogiorgou P; Hegerl U
J Clin Psychiatry; 2007 Aug; 68(8):1206-12. PubMed ID: 17854244
[TBL] [Abstract][Full Text] [Related]
30. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
Papakostas GI; Nelson JC; Kasper S; Möller HJ
Eur Neuropsychopharmacol; 2008 Feb; 18(2):122-7. PubMed ID: 17719752
[TBL] [Abstract][Full Text] [Related]
31. Noradrenaline and serotonin reuptake inhibition as clinical principles: a review of antidepressant efficacy.
Humble M
Acta Psychiatr Scand Suppl; 2000; 402():28-36. PubMed ID: 10901156
[TBL] [Abstract][Full Text] [Related]
32. Severity of depression and response to antidepressants: GENPOD randomised controlled trial.
Wiles NJ; Mulligan J; Peters TJ; Cowen PJ; Mason V; Nutt D; Sharp D; Tallon D; Thomas L; O'Donovan MC; Lewis G
Br J Psychiatry; 2012 Feb; 200(2):130-6. PubMed ID: 22194183
[TBL] [Abstract][Full Text] [Related]
33. Fluoxetine versus other types of pharmacotherapy for depression.
Magni LR; Purgato M; Gastaldon C; Papola D; Furukawa TA; Cipriani A; Barbui C
Cochrane Database Syst Rev; 2013 Jul; (7):CD004185. PubMed ID: 24353997
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: a pooled analysis.
Pjrek E; Konstantinidis A; Assem-Hilger E; Praschak-Rieder N; Willeit M; Kasper S; Winkler D
J Psychiatr Res; 2009 May; 43(8):792-7. PubMed ID: 19230909
[TBL] [Abstract][Full Text] [Related]
35. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine.
Berlanga C; Flores-Ramos M
J Affect Disord; 2006 Oct; 95(1-3):119-23. PubMed ID: 16782204
[TBL] [Abstract][Full Text] [Related]
36. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder.
Clayton AH; Zajecka J; Ferguson JM; Filipiak-Reisner JK; Brown MT; Schwartz GE
Int Clin Psychopharmacol; 2003 May; 18(3):151-6. PubMed ID: 12702894
[TBL] [Abstract][Full Text] [Related]
37. The antidepressant efficacy of reboxetine in patients with severe depression.
Montgomery S; Ferguson JM; Schwartz GE
J Clin Psychopharmacol; 2003 Feb; 23(1):45-50. PubMed ID: 12544375
[TBL] [Abstract][Full Text] [Related]
38. Reboxetine--another new antidepressant.
Drug Ther Bull; 1998 Nov; 36(11):86-8. PubMed ID: 10562766
[TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis.
Sun Y; Liang Y; Jiao Y; Lin J; Qu H; Xu J; Zhao C
BMJ Open; 2017 Aug; 7(8):e016499. PubMed ID: 28775189
[TBL] [Abstract][Full Text] [Related]
40. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
Fava M; McGrath PJ; Sheu WP;
J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
